{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:42:28Z","timestamp":1788529348059,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Swedish Cancer Society","award":["21-1684"],"award-info":[{"award-number":["21-1684"]}]},{"name":"The B Kamprad Foundation","award":["FBKS 2019-28"],"award-info":[{"award-number":["FBKS 2019-28"]}]},{"DOI":"10.13039\/100016290","name":"The Cancer and Allergy Foundation","doi-asserted-by":"crossref","award":["10672 (2022)"],"award-info":[{"award-number":["10672 (2022)"]}],"id":[{"id":"10.13039\/100016290","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Governmental funding of clinical research within the National Health Services","award":["40615 (2022)"],"award-info":[{"award-number":["40615 (2022)"]}]},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Tertiary lymphoid structures (TLS) in the tumor microenvironment are prognostically beneficial in many solid cancer types. Reports on TLS in high-grade serous tubo-ovarian carcinoma (HGSC) are few, and the prognostic impact is unclear. We investigated mature TLS (mTLS), immature TLS (iTLS) and lymphoid aggregates (LA) in primary adnexal tumors (PTs) and synchronous omental\/peritoneal metastases (pMets) of HGSC. Whole H&amp;E slides were scrutinized for mTLS and LA in a population-based cohort of 130 cases with stage III-IV HGSC. The immune cell tumor infiltration was evaluated with single chromogenic immunohistochemistry (IHC) on a tissue microarray (TMA) from the same cases. Selected whole slides (PT\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200911, pMet\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200910) of the cases most abundant in mTLS and LA were further investigated with multiplex IHC and immunofluorescence using digital image analysis (QuPath), to confirm TLS status and map the T and B lymphocyte subtypes. The results showed that mTLS were more common in pMets than in PTs but did not have an independent prognostic impact on overall or progression-free survival. The presence of mTLS correlated with intratumoral infiltration of CD8\n                    <jats:sup>+<\/jats:sup>\n                    cytotoxic T cells, FOXP3\n                    <jats:sup>+<\/jats:sup>\n                    regulatory T cells and PD-1\n                    <jats:sup>+<\/jats:sup>\n                    lymphocytes in pMets only. Although overall mTLS cell composition was similar between PTs and pMets, the outer zones of mTLS in PTs were more immune cell-rich. In conclusion, our results indicate differences in TLS presence and cellular elements between primary adnexal tumors and synchronous peritoneal metastases, which are important to consider when conducting studies of the immune environment in HGSC.\n                  <\/jats:p>","DOI":"10.1007\/s00262-024-03911-2","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T04:54:12Z","timestamp":1735880052000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tertiary lymphoid structures in high-grade serous tubo-ovarian carcinoma: anatomical site matters"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4365-371X","authenticated-orcid":false,"given":"Sofia","family":"Westbom-Fremer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ebbesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3618-8282","authenticated-orcid":false,"given":"Laura","family":"Martin de la Fuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6208-7813","authenticated-orcid":false,"given":"Jenny-Maria","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5517-1494","authenticated-orcid":false,"given":"P\u00e4ivi","family":"Kannisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7328-6239","authenticated-orcid":false,"given":"Srinivas","family":"Veerla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6840-3397","authenticated-orcid":false,"given":"Ingrid","family":"Hedenfalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"issue":"7353","key":"3911_CR1","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"CGAR Network","year":"2011","unstructured":"Network CGAR (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609\u2013615. https:\/\/doi.org\/10.1038\/nature10166","journal-title":"Nature"},{"issue":"1","key":"3911_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/path.4230","volume":"231","author":"A Bashashati","year":"2013","unstructured":"Bashashati A et al (2013) Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol 231(1):21\u201334. https:\/\/doi.org\/10.1002\/path.4230","journal-title":"J Pathol"},{"issue":"3","key":"3911_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/modpathol.2008.191","volume":"22","author":"B Clarke","year":"2009","unstructured":"Clarke B et al (2009) Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 22(3):393\u2013402. https:\/\/doi.org\/10.1038\/modpathol.2008.191","journal-title":"Mod Pathol"},{"issue":"7","key":"3911_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006412","volume":"4","author":"K Milne","year":"2009","unstructured":"Milne K et al (2009) Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS ONE 4(7):e6412. https:\/\/doi.org\/10.1371\/journal.pone.0006412","journal-title":"PLoS ONE"},{"issue":"12","key":"3911_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3290","volume":"3","author":"EL Goode","year":"2017","unstructured":"Goode EL et al (2017) Dose-response association of CD8+ Tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol 3(12):e173290. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3290","journal-title":"JAMA Oncol"},{"issue":"7941","key":"3911_CR6","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","volume":"612","author":"I Vazquez-Garcia","year":"2022","unstructured":"Vazquez-Garcia I et al (2022) Ovarian cancer mutational processes drive site-specific immune evasion. Nature 612(7941):778\u2013786. https:\/\/doi.org\/10.1038\/s41586-022-05496-1","journal-title":"Nature"},{"issue":"7","key":"3911_CR7","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","volume":"30","author":"UA Matulonis","year":"2019","unstructured":"Matulonis UA et al (2019) Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol 30(7):1080\u20131087. https:\/\/doi.org\/10.1093\/annonc\/mdz135","journal-title":"Ann Oncol"},{"issue":"12","key":"3911_CR8","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-15-2762","volume":"22","author":"DR Kroeger","year":"2016","unstructured":"Kroeger DR, Milne K, Nelson BH (2016) Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin Cancer Res 22(12):3005\u20133015. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2762","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3911_CR9","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1007\/s43032-023-01188-x","volume":"30","author":"K Zhang","year":"2023","unstructured":"Zhang K et al (2023) Tertiary lymphoid structures are associated with a favorable prognosis in high-grade serous ovarian cancer patients. Reprod Sci 30(8):2468\u20132480. https:\/\/doi.org\/10.1007\/s43032-023-01188-x","journal-title":"Reprod Sci"},{"issue":"1","key":"3911_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001136","volume":"9","author":"M Yang","year":"2021","unstructured":"Yang M et al (2021) CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer. J Immunother Cancer 9(1):e001136. https:\/\/doi.org\/10.1136\/jitc-2020-001136","journal-title":"J Immunother Cancer"},{"issue":"12","key":"3911_CR11","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157215","volume":"7","author":"M Ukita","year":"2022","unstructured":"Ukita M et al (2022) CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. JCI Insight 7(12):e157215. https:\/\/doi.org\/10.1172\/jci.insight.157215","journal-title":"JCI Insight"},{"issue":"1","key":"3911_CR12","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1038\/s41467-024-46873-w","volume":"15","author":"L Kasikova","year":"2024","unstructured":"Kasikova L et al (2024) Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer. Nat Commun 15(1):2528. https:\/\/doi.org\/10.1038\/s41467-024-46873-w","journal-title":"Nat Commun"},{"issue":"4","key":"3911_CR13","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/JLB.5MIR0720-271RR","volume":"109","author":"M Liu","year":"2021","unstructured":"Liu M et al (2021) Specialized immune responses in the peritoneal cavity and omentum. J Leukoc Biol 109(4):717\u2013729. https:\/\/doi.org\/10.1002\/JLB.5MIR0720-271RR","journal-title":"J Leukoc Biol"},{"key":"3911_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/bs.ircmb.2022.04.015","volume":"371","author":"J Demuytere","year":"2022","unstructured":"Demuytere J et al (2022) The tumor immune microenvironment in peritoneal carcinomatosis. Int Rev Cell Mol Biol 371:63\u201395. https:\/\/doi.org\/10.1016\/bs.ircmb.2022.04.015","journal-title":"Int Rev Cell Mol Biol"},{"issue":"1","key":"3911_CR15","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1038\/s41467-019-11036-9","volume":"10","author":"X Fan","year":"2019","unstructured":"Fan X et al (2019) Single-cell reconstruction of follicular remodeling in the human adult ovary. Nat Commun 10(1):3164. https:\/\/doi.org\/10.1038\/s41467-019-11036-9","journal-title":"Nat Commun"},{"issue":"1","key":"3911_CR16","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/s41467-020-14936-3","volume":"11","author":"M Wagner","year":"2020","unstructured":"Wagner M et al (2020) Single-cell analysis of human ovarian cortex identifies distinct cell populations but no oogonial stem cells. Nat Commun 11(1):1147. https:\/\/doi.org\/10.1038\/s41467-020-14936-3","journal-title":"Nat Commun"},{"issue":"7","key":"3911_CR17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","volume":"19","author":"WH Fridman","year":"2022","unstructured":"Fridman WH et al (2022) B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol 19(7):441\u2013457. https:\/\/doi.org\/10.1038\/s41571-022-00619-z","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"3911_CR18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.4161\/onci.20492","volume":"1","author":"L Martinet","year":"2012","unstructured":"Martinet L et al (2012) High endothelial venules (HEVs) in human melanoma lesions: major gateways for tumor-infiltrating lymphocytes. Oncoimmunology 1(6):829\u2013839. https:\/\/doi.org\/10.4161\/onci.20492","journal-title":"Oncoimmunology"},{"issue":"8","key":"3911_CR19","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1158\/1078-0432.CCR-13-2590","volume":"20","author":"G Di Caro","year":"2014","unstructured":"Di Caro G et al (2014) Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin Cancer Res 20(8):2147\u20132158. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2590","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3911_CR20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1158\/0008-5472.CAN-13-1342","volume":"74","author":"J Goc","year":"2014","unstructured":"Goc J et al (2014) Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res 74(3):705\u2013715. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1342","journal-title":"Cancer Res"},{"issue":"1","key":"3911_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00428-020-02751-6","volume":"477","author":"L Martin Fuente","year":"2020","unstructured":"Martin Fuente L et al (2020) PD-1\/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma. Virchows Arch 477(1):83\u201391. https:\/\/doi.org\/10.1007\/s00428-020-02751-6","journal-title":"Virchows Arch"},{"issue":"1","key":"3911_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","volume":"124","author":"J Prat","year":"2014","unstructured":"Prat J, Oncology FCOG (2014) Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 124(1):1\u20135. https:\/\/doi.org\/10.1016\/j.ijgo.2013.10.001","journal-title":"Int J Gynaecol Obstet"},{"key":"3911_CR23","unstructured":"Female Genital Tumours\/WHO Classification of Tumours. 5 ed. Vol. 4. 2020: Lyon: International Agency for Research on Cancer"},{"issue":"4","key":"3911_CR24","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","volume":"21","author":"GCE Stuart","year":"2011","unstructured":"Stuart GCE et al (2011) Gynecologic cancer intergroup (GCIG) consensus statement on clinical trials in Ovarian Cancer: report from the fourth ovarian cancer consensus conference. Int J Gynecol Cancer 21(4):750\u2013755. https:\/\/doi.org\/10.1097\/IGC.0b013e31821b2568","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"3911_CR25","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3390\/cancers13020254","volume":"13","author":"JM Jonsson","year":"2021","unstructured":"Jonsson JM et al (2021) Homologous recombination repair mechanisms in serous endometrial cancer. Cancers 13(2):254. https:\/\/doi.org\/10.3390\/cancers13020254","journal-title":"Cancers"},{"issue":"1","key":"3911_CR26","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P et al (2017) QuPath: open source software for digital pathology image analysis. Sci Rep 7(1):16878. https:\/\/doi.org\/10.1038\/s41598-017-17204-5","journal-title":"Sci Rep"},{"key":"3911_CR27","unstructured":"Team RC (2021) R: a language and environment for statistical computing"},{"key":"3911_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: Elegant Graphics for Data Analysis","author":"H Wickham","year":"2016","unstructured":"Wickham H (2016) ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag, New York"},{"issue":"1","key":"3911_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41379-018-0113-8","volume":"32","author":"M Lee","year":"2019","unstructured":"Lee M et al (2019) Presence of tertiary lymphoid structures determines the level of tumor-infiltrating lymphocytes in primary breast cancer and metastasis. Mod Pathol 32(1):70\u201380. https:\/\/doi.org\/10.1038\/s41379-018-0113-8","journal-title":"Mod Pathol"},{"issue":"6576","key":"3911_CR30","doi-asserted-by":"publisher","first-page":"eabf9419","DOI":"10.1126\/science.abf9419","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher TN, Thommen DS (2022) Tertiary lymphoid structures in cancer. Science 375(6576):eabf9419. https:\/\/doi.org\/10.1126\/science.abf9419","journal-title":"Science"},{"issue":"9","key":"3911_CR31","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1158\/1078-0432.CCR-21-1130","volume":"28","author":"M Lauss","year":"2022","unstructured":"Lauss M et al (2022) B cells and tertiary lymphoid structures: friends or foes in cancer immunotherapy? Clin Cancer Res 28(9):1751\u20131758. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1130","journal-title":"Clin Cancer Res"},{"issue":"10","key":"3911_CR32","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1097\/gme.0000000000000221","volume":"21","author":"R Maruoka","year":"2014","unstructured":"Maruoka R et al (2014) Ovarian estradiol production and lipid metabolism in postmenopausal women. Menopause 21(10):1129\u20131135. https:\/\/doi.org\/10.1097\/gme.0000000000000221","journal-title":"Menopause"},{"issue":"1","key":"3911_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12974-020-01998-9","volume":"17","author":"M McCarthy","year":"2020","unstructured":"McCarthy M, Raval AP (2020) The peri-menopause in a woman\u2019s life: a systemic inflammatory phase that enables later neurodegenerative disease. J Neuroinflammation 17(1):317. https:\/\/doi.org\/10.1186\/s12974-020-01998-9","journal-title":"J Neuroinflammation"},{"issue":"8","key":"3911_CR34","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","volume":"2","author":"L Vanhersecke","year":"2021","unstructured":"Vanhersecke L et al (2021) Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer 2(8):794\u2013802. https:\/\/doi.org\/10.1038\/s43018-021-00232-6","journal-title":"Nat Cancer"},{"key":"3911_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690105","volume":"12","author":"JN Filderman","year":"2021","unstructured":"Filderman JN et al (2021) STINGing the tumor microenvironment to promote therapeutic tertiary lymphoid structure development. Front Immunol 12:690105. https:\/\/doi.org\/10.3389\/fimmu.2021.690105","journal-title":"Front Immunol"},{"key":"3911_CR36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2117754119","author":"SV Paffenholz","year":"2022","unstructured":"Paffenholz SV et al (2022) Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer. Proc Nat Acad Sci. https:\/\/doi.org\/10.1073\/pnas.2117754119","journal-title":"Proc Nat Acad Sci"},{"issue":"1","key":"3911_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-023-00609-z","volume":"10","author":"M Chen","year":"2024","unstructured":"Chen M et al (2024) cGAS-STING pathway expression correlates with genomic instability and immune cell infiltration in breast cancer. NPJ Breast Cancer 10(1):1. https:\/\/doi.org\/10.1038\/s41523-023-00609-z","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"3911_CR38","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/cncr.34582","volume":"129","author":"EY Kang","year":"2023","unstructured":"Kang EY et al (2023) CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: an ovarian tumor tissue analysis consortium study. Cancer 129(5):697\u2013713. https:\/\/doi.org\/10.1002\/cncr.34582","journal-title":"Cancer"},{"issue":"23","key":"3911_CR39","doi-asserted-by":"publisher","first-page":"5965","DOI":"10.3390\/cancers14235965","volume":"14","author":"L van Wagensveld","year":"2022","unstructured":"van Wagensveld L et al (2022) Homologous recombination deficiency and cyclin E1 amplification are correlated with immune cell infiltration and survival in high-grade serous ovarian cancer. Cancers 14(23):5965. https:\/\/doi.org\/10.3390\/cancers14235965","journal-title":"Cancers"},{"issue":"6","key":"3911_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101055","volume":"4","author":"P Cunnea","year":"2023","unstructured":"Cunnea P et al (2023) Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: implications for surgical and clinical outcomes. Cell Rep Med 4(6):101055. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101055","journal-title":"Cell Rep Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03911-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03911-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03911-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T20:09:49Z","timestamp":1739131789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03911-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["3911"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03911-2","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"5 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report there are no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This study was performed in line with the principals of the Declaration of Helsinki. Ethical approval was granted by the Ethics Committee at Lund University, Sweden (EPN 2014\/717), waiving the requirement for further informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Consent to participate, with possibility to opt out at any timepoint, in studies involving the archived tissue was given at the time of tissue submission and referral to the pathology department. As this study had a retrospective design, the ethics approval waived the requirement for written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"56"}}